Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment

28 Jul 2021

Abstract excerpt

Oncolytic herpes simplex viruses (oHSVs) have demonstrated efficient lytic replication in human glioblastoma tumors using immunodeficient mouse models, but early-phase clinical trials have reported few complete responses. Potential reasons for the lack of efficacy are limited vector potency and the suppressive glioma tumor microenvironment (TME). Here we compare the oncolytic activity of two HSV-1 vectors, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Glioma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34553031
DOI: 10.1016/j.omto.2021.07.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitmentPMID 34553031Read ↗

Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cellsSemantic proximity Read ↗

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomasSemantic proximity Read ↗

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunitySemantic proximity Read ↗

Virus-Based Therapies for the Treatment of Recurrent High-Grade GliomaSemantic proximity Read ↗

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastomaSemantic proximity Read ↗

Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.Semantic proximity Read ↗

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read ↗

IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastomaSemantic proximity Read ↗

Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principleSemantic proximity Read ↗

Towards an armed oncolytic virus approach to glioblastoma treatmentSemantic proximity Read ↗

Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma.Semantic proximity Read ↗

Polio Virotherapy of Malignant Glioma Engages the Tumor Myeloid Infiltrate and Induces Diffuse Microglia ActivationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.